Skip to main content

Degussa Corp. to Take Full Control of Proligo

NEW YORK, Aug. 22 – Gilead Sciences is selling its 49 percent interest in oligonucleotides manufacturer Proligo to Degussa Corporation, which currently holds the remaining Proligo shares, the company announced on Wednesday.

The deal, expected to close on Aug. 31, is for $14 million in cash, according to Foster City, Calif.-based Gilead.

Proligo is a joint venture between Gilead and SKW Americas, a subsidiary of Parsippany, NJ-based Degussa. Proligo of Boulder, Colo. sells standard and specialty monomers for oligonucleotide synthesis and probes. Degussa was entitled to purchase Gilead’s interest in Proligo as part of the terms of Gilead’s 1998 merger with NeXstar Pharmaceuticals, which originally formed Proligo in a joint venture with SKW Americas.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.